Tag: AstraZeneca

Startup RQ Biotechnology received $157 million from AstraZeneca for Covid antibodies

RQ Bio emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of...

Sales of AstraZeneca’s COVID vaccine exceed forecasts Q1 revenue $11.39 billion

AstraZeneca PLC said Friday that it expects sales of total revenue from COVID-19 medicines is anticipated to decline by...

FDA declines to approve AstraZeneca treatment for chronic nasal condition

AstraZeneca Plc said on Monday the U.S. drug regulator declined to approve its asthma medicine, Fasenra, for treatment of...

U.S FDA approves drug to treat early breast cancer

AstraZeneca and Merck reported today, Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients...

AstraZeneca, Honeywell to develop respiratory inhalers with near-zero GWP propellants

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9%...

Clinical trials in Russia and Azerbaijan of the combination of AstraZeneca and Sputnik Light vaccines showed safety

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), R-Pharm group and AstraZeneca announce interim results of phase...

New investments in the innovative biotechnology company “Target Medicals”

RDIF, AstraZeneca and Unicorn Capital Partners invest in Target Medicals, developing aldosterone synthase inhibitor for the treatment of resistant...

Russia approves AstraZeneca’s drug for coronavirus prophylaxis

The Russian Ministry of Health approved circulation of Evusheld, a COVID-19 prophylaxis drug by AstraZeneca, on the territory of...

AstraZeneca and Neurimmune sign exclusive global collaboration to develop and commercialise NI006

Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for...

The combination of AstraZeneca and Sputnik Light vaccines in Azerbaijan shows strong neutralizing antibodies growth

R-Pharm Group, the Russian Direct Investment Fund (RDIF) and AstraZeneca announce preliminary virus neutralizing activity results of combined use...

A combination between AstraZeneca and Sputnik Light demonstrates high immunogenicity profile

Clinical trials in Azerbaijan began in February 2021. To date 64 volunteers have been vaccinated, the enrollment of volunteers is ongoing.

Combination of the Sputnik Light with others vaccines demonstrates high safety profile

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.